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A b s t r a c t
Background: Diabetes mellitus is a quite frequent comorbidity among patients with acute coronary syndromes (ACS). The presence
of diabetes has also predicted poor outcome after lower limb percutaneous transluminal angioplasty (PTA). 
Aim: To determine outcomes of patients with and without diabetes mellitus treated with PCI and PTA at index hospital stay
during a 12-month follow-up.  
Material and methods: There were 116 NSTACS (non ST elevation acute coronary syndromes) patients gathered in this prospective
registry study in 2003-2009 in one academic center in Krakow, Poland.
Results: Data on consecutive patients who underwent PTA and PCI procedure during the same hospital stay were analyzed. Of
these, 16 (14%) had diabetes mellitus, the other 100 (86%) had no history of diabetes. Both groups differed significantly with regard
to gender and past medical history. During one-year observation 12.5% patients died in diabetes group vs. 2% in non-diabetes group
(p = 0.033). Diabetes mellitus has turned out to be a strong predictor of outcome measured by the occurrence of repeated percutaneous
peripheral procedure in 12-month observation.
Conclusions: Patients with diabetes mellitus have more aggravating past medical history with more frequently coexisting
comorbidities. Diabetes mellitus in patients with ACS treated by PCI and PTA is associated with impaired 1-year survival. Diabetes
itself is a strong predictor of repeated PTA procedures.    
Key words: peripheral angioplasty, diabetes, acute coronary syndrome, limb ischaemia 
S t r e s z c z e n i e
Wstęp: Współwystępowanie cukrzycy i ostrych zespołów wieńcowych (OZW) jest częstym zjawiskiem. Obecność cukrzycy jest
predyktorem niekorzystnego rokowania chorych po zabiegach przezskórnej angioplastyki tętnic kończyn dolnych (ang. percutaneous
transluminal angioplasty, PTA). 
Cel: Porównanie bezpośrednich wyników leczenia chorych z cukrzycą i bez cukrzycy metodą przezskórnej interwencji wieńcowej
(ang. percutaneous coronary intervention, PCI) oraz PTA w czasie tej samej hospitalizacji oraz określenie wyników leczenia 
w 12-miesięcznej obserwacji.  
Materiał i metody: Stu szesnastu chorych z OZW bez uniesienia odcinka ST zostało włączonych do prospektywnego rejestru
w czasie badania w latach 2003–2009 w jednym centrum akademickim w Krakowie.
Wyniki: Analizowano dane chorych, którzy przebyli procedury PCI i PTA w czasie jednego pobytu szpitalnego. Spośród tych chorych
16 (14%) miało rozpoznaną cukrzycę, pozostali nie byli leczeni z tego powodu [100 (86%)]. Obie grupy różniły się istotnie statysty-
cznie ze względu na płeć i wywiad. W ciągu rocznej obserwacji 12,5% osób zmarło w grupie chorych na cukrzycę w przeciwieństwie
do 2% zgonów w grupie chorych bez cukrzycy (p = 0,033). Cukrzyca okazała się również silnym czynnikiem konieczności wykona-
nia ponownych interwencji przezskórnych w ciągu 12-miesięcznej obserwacji.
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Introduction
Diabetes mellitus is a quite frequent comorbidity
among patients with acute coronary syndromes (ACS) 
[1-3]. It is also an established predictor of impaired in-
hospital and long-term outcome in ACS patients treated
with percutaneous coronary interventions (PCI) [2, 4]. Some
studies suggest that glycaemia itself rather than past
medical history of diabetes is a better and stronger
determinant of survival [5, 6]. 
Diabetic patients are at high risk for peripheral arterial
disease [7]. It is quite common that the atherosclerosis
coexists in many arterial beds – in coronary artery disease
patients in up to 30% of the cases. The presence of
diabetes has also predicted poor outcome after lower limb
percutaneous transluminal angioplasty (PTA) [8]. There are
still insufficient data concerning long-term clinical outcome
for patients with diabetes treated with PTA, especially in
the setting of ACS. 
The aim of this registry study was to determine
outcomes of patients with and without diabetes treated
with PCI and PTA during index hospital stay during a 12-
month follow-up.  
Material and methods
Patients with the diagnosis of non-ST elevation acute
coronary syndrome (NSTE ACS) treated with percutaneous
coronary intervention (PCI) and PTA during the same
hospital stay were enrolled in this registry study in 
2003-2009. PTA was performed only in patients with critical
lesions in lower limb arteries confirmed in angiography
and in patients with the duration of clinical symptoms of
limb ischaemia of at least 3 months (intermittent
claudication). Study conduct and patient enrollment was
performed according to the Declaration of Helsinki and
general GCP rules. Detailed study rationale and methods
have been previously published [9-11].
Patients were divided into two groups: patients with
diabetes mellitus (DM+) and those without diabetes (DM–).
The diagnosis of diabetes mellitus was based upon past
medical history, patient documentation and/or intake of
oral hypoglicaemic agents or insulin. 
Study primary efficacy endpoint was the occurrence of
major adverse cardiac and cerebrovascular event (MACCE)
in 12-month follow-up. Major adverse ischaemic events
(MACCE) were defined as the occurrence of death, repeated
myocardial infarction, urgent coronary revascularization
(PCI or CABG) or ischeaemic stroke/transient ischaemic
attack (TIA). 
Secondary endpoint was defined as the occurrence of
MAPE (Major Adverse Peripheral Event) during a 12-month
observation (repeated PTA, ischaemic stroke/TIA or
amputation due to limb ischaemia or its complications). 
In-hospital bleeding complications were defined as
the occurrence of major bleeding requiring blood
transfusion. 
Clinical long-term follow-up was performed in the 12th
month after index procedures by a dedicated physician
with ultrasonography and ankle-brachial index (ABI)
assessment. Telephone contact was advised only in cases
in which the patient was unable to attend the visit at the
out-patient department. 
Registry data were analyzed according to the accepted
standards of descriptive statistics. Categorical data were
compared using χ2 and Fisher exact tests. These data were
presented as percentages. Continuous data were presented
as means ± standard deviation and compared between
the groups using two-sided U Mann-Whitney test. Event
free survival curves were plotted by Kaplan-Meier estimator
with long-rank test to search for differences between
patients with and without diabetes mellitus. A logistic
regression model for independent predictors of rePTA was
built. Predictors which were significant (p < 0.1) in
univariate analysis were included in multivariate analysis.
A p value of < 0.05 was considered statistically significant.
All calculations were performed using STATISTICA 8.0
software (Statsoft Inc., Tulsa, OK., USA).
Results
Data on 116 consecutive patients who underwent PTA
and PCI procedure during the same hospital stay were
analyzed. Of these, 16 (14%) had diabetes mellitus, the
other 100 (86%) had no history of diabetes. Both groups
differed significantly with regard to gender and past
medical history (tab. 1). No differences were observed
though in the clinical magnitude of lower limb ischemia
as measured by Fontaine scale and claudication distance. 
Details concerning the character and location of
atherosclerotic disease in lower limb arteries as well as
result of the PTA procedures are depicted in table 2.
A median time from PCI to PTA procedure (the same
hospital stay) was similar between the groups (DM+ vs.
DM–: 4.1 ±1.5 vs. 4.0 ±1.7 days, p = NS). One patient in DM+
group (6.25%) and five patients in DM– group (5%) had
PTA procedure immediately following PCI. 
During one-year observation 12.5% patients died in
diabetes group vs. 2% in non-diabetes group (p = 0.033).
Wnioski: Pacjenci z cukrzycą mieli bardziej obciążający wywiad chorobowy z licznymi chorobami towarzyszącymi. Obecność
cukrzycy u chorych z OZW leczonych metodą PCI i PTA jest związana z istotnie pogorszonym przeżyciem w 12-miesięcznej obserwacji.
Cukrzyca jest ponadto silnym predyktorem konieczności ponownych rewaskularyzacji przezskórnych.    
Słowa kluczowe: interwencje obwodowe, cukrzyca, ostry zespół wieńcowy, niedokrwienie kończyn dolnych
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Other ischaemic events occurred similarly in both study
groups in long-term follow-up (tab. 3).    
In order to reduce selection bias typical for registries
multivariate regression analysis was performed to
determine independent predictors of repeated PTA
procedure due to restenosis. Diabetes mellitus has turned
out to be among others a strong predictor of outcome
measured by repeated percutaneous peripheral procedure
in 12-month follow-up (tab. 4). 
Moreover, figures 1 and 2 depict Kaplan-Meier event
free survival curves for MACCE and MAPE respectively in
both study groups (DM+ and DM–). No significant
differences have been shown.  
Discussion
The main cause of PAD is the process of forming
atherosclerotic plaques. Risk factors which promote 
plaque formation include smoking habit, diabetes,
hypercholesterolemia, hypertension and hyperhomo -
cysteinaemia. 
The occurrence of PAD in general population varies
from 3 to 10% with the rise in elderly patients to up to 25%
[15]. It is also worth noticing that CAD often coexists with
PAD in almost as much as 30% of cases. Jeremias et al.
revealed that PAD coexisted in 5.9% of patients with acute
myocardial infarction treated by PCI [12]. Even after
adjusting for the baseline and procedural characteristics,
PAD remained an independent predictor of in-hospital
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DM+ DM– p
Gender (males) [%] 63 84 0.042*
Age [years] 63.4 ±7.8 61.8 ±9.3 0.357
BMI [kg/m2] 26.5 ±3.2 25.9 ±3.1 0.652
Prior angina [%] 100 49 < 0.001*
Previous MI [%] 69 36 0.013 *
Hypertension [%] 100 50 < 0.001*
Hypercholesterolaemia [%] 94 42 < 0.001 *
Current smoker [%] 50 28 0.077 
Prior stroke / TIA [%] 38 5 < 0.001 *
Fontaine scale [%]
1 0 9 0.822
2a 17 19
2b 83 69
3 0 3
Claudication distance [meters] 92 ±79 118 ±169 0.852
Table 1. Demographic data and medical history
Tabela 1. Dane demograficzne i wywiad chorobowy
pacjentów
DM – diabetes mellitus, BMI – body mass index, TIA – transient
ischaemic attack, MI – myocardial infarction 
DM – cukrzyca, BMI – indeks masy ciała, TIA – przejściowy atak
niedokrwienny, MI – zawał serca 
DM+ DM– p
Artery [%]
Common iliac 19 43 0.073
Superficial femoral 81 51
Femoral 0 6
Stenting during PTA [%] 62 38 0.072
Satisfactory PTA result [%] 86 85 0.912
Table 2. Angiography and percutaneous translu-
minal angioplasty data
Tabela 2. Dane dotyczące badania angiograficznego
i zabiegu PTA
DM – diabetes mellitus, PTA – percutaneous transluminal angioplasty
DM – cukrzyca, PTA – angioplastyka przezskórna
Fig. 1. MACCE free survival in 1-year follow-up by
Kaplan-Meier
MACCE – major adverse cerebrovascular and cardiac events
Ryc. 1. Krzywa Kaplana-Meiera 1-rocznego przeży-
cia chorych wolnego od MACCE
MACCE – główne mózgowo-naczyniowe i sercowe zdarzenia niepożądane
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Fig. 2. MAPE free survival in 1-year follow-up by
Kaplan-Meier
MAPE – major adverse peripheral events
Ryc. 2. Krzywa Kaplana-Meiera 1-rocznego przeży-
cia chorych wolnego od MAPE
MAPE – główne zdarzenia niepożądane dotyczące naczyń obwodowych
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mortality in this study (odds ratio 2.2, 95% confidence
interval 1.7 to 3.0, p < 0.001). In the REACH registry 1-year
mortality was 12.6% in patients with atherosclerosis in one
arterial bed and 26.3% in those with atherosclerosis in
three beds [13]. Multilevel atherosclerosis requires thus
additional attention since it significantly impairs clinical
outcome.  
Duran et al. found out that arterial hypertension and
diabetes were independent predictors of multilevel
atherosclerotic disease [14]. Moreover, the frequency of
adverse clinical events was significantly higher in patients
with PAD (20.4% vs. 7.0%, p < 0.001) as well as mortality
in long-term follow-up (13% vs. 3.8%, p <0.001).
The diagnosis, predisposing factors and treatment of
PAD are described in the current TASC II guidelines.
Compared with the original TASC guidelines more 
emphasis has been put on the association of diabetes 
and PAD [16]. Multiple studies have shown an association
between diabetes mellitus and the development of PAD.
Intermittent claudication is about twice as common in
diabetic patients. Additional evidence suggest that insulin
resistance plays a major role in a clustering of cardio -
metabolic risk factors like hyperglycemia, dyslipidemia,
obesity and hypertension. PAD in patients with diabetes
is more aggressive in terms of outcome and complications
compared to those without diabetes. Amputation rates 
are 5-10 times higher in diabetics. Based on many
observations, a consensus statement from the American
Diabetes Association recommends PAD screening with an
ABI every 5 years in patients with diabetes. Several studies
revealed that aggressive lowering of glycaemia may prevent
microvascular complications, however, this has not been
demonstrated for PAD probably because the studies
conducted so far examining glycemic control in diabetes
were underpowered to study PAD endpoints. 
There are very limited data concerning clinical outcome
in patients with ACS treated by PCI which also present with
clinically and angiographically significant PAD. Our registry
study is one of the first to describe such patients [9-10]. In
the current analysis we tried to predict outcome in diabetic
patients which are known to have poor survival not only
after coronary PCI procedures but also after PTA [8, 12].
As expected, patients with diabetes mellitus in our
study turned out to be at higher risk due to co-existing
comorbidities. But one must also take into account the
relatively small number of patients enrolled. The only
clinical parameter that was significant was 1-year death
which was surely influenced by other factors. On the other
hand, diabetes turned out to be an independent predictor
of repeated PTA procedure which is also a marker of the
progression of atheroscelrosis in general, also in the
coronary bed. 
Performing PTA and PCI procedures together (as in
minority of our patients) or during one hospital stay (100%)
may be associated with additional exposure radiation and
contrast volumes that may impair renal function. Although
significantly larger amounts of contrast media and
radiation were used for PCI (especially multivessel PCI) than
PTA, no substantial rise in contrast nephropathy was
noticed in our registry population [11, 17]. 
The results of our study indicate that the presence of
diabetes may impair the outcome of  our coronary and
DM+ DM– p
n = 16 n = 100
Death [%] 12.5 2 0.033 *
Myocardial infarction 0 2 0.568
(STEMI + NSTEMI) [%]
Stroke / TIA [%] 6.3 2 0.320
PCI [%] 6.3 3 0.508
rePTA [%] 6.3 9 0.716
Elective PTA of arteries other than 0 5 0.361
index ones [%]
Lower limb amputation [%] 0 1 0.687
Death + myocardial infarction [%] 12.5 4 0.154
Death + myocardial infarction 18.8 7 0.119
+ stroke/TIA + urgent coronary 
revascularization (MACCE) [%]
rePTA + stroke/TIA + amputation 12.5 11 0.859
(MAPE) [%]
In-hospital bleeding complications [%] 0 0 -
Table 3. Results of 12-month clinical follow-up 
Tabela 3. Wyniki 12-miesięcznych obserwacji klini cz -
nych
DM – diabetes mellitus, STEMI – ST elevation myocardial infarction,
NSTEMI – non-ST elevation myocardial infarction, TIA – transient
ischaemic attack, PTA – percutaneous transluminal angioplasty, MACCE
– major adverse cerebrovascular and cardiac events, MAPE – major
adverse peripheral events 
DM – cukrzyca, STEMI – zawał serca z uniesieniem odcinka ST, NSTEMI
– zawał serca bez uniesienia odcinka ST, TIA – przejściowy atak
niedokrwienny, PTA – angioplastyka przezskórna, MACCE – główne
mózgowo-naczyniowe i sercowe zdarzenia niepożądane, MAPE –
główne zdarzenia niepożądane dotyczące naczyń obwodowych
OR 95% CI p
Unsatisfactory result of PTA 3.04 1.41–4.95 0.011
procedure (suboptimal, dissection, 
residual narrowing)
Hypercholesterolaemia 1.33 1.10–1.61 0.041
Diabetes mellitus 2.52 1.03–5.51 0.045
Multivessel disease in coronary 2.06 1.45–2.61 0.018
angiography
Current smoker 2.05 1.01–3.56 0.049
Table 4. Multivariate regression analysis model for
independent predictors of repeated PTA
Tabela 4. Wieloczynnikowa analiza regresji dla
niezależnych czynników ryzyka powtórnej PTA
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peripheral procedures in terms of hard endpoints like
death. It seems that adequate glicaemia control and statin
therapy to control lipid levels and promote plaque
stabilization is essential. Those factors were among others
to independently predict restenosis. Finally, complete
revascularization not only within the coronary tree is crucial
for patients who require post ACS cardiac rehabilitation.
Claudication and limb ischaemia may prevent those
patients from proper secondary prevention. Adequate
perfusion of lower limbs in diabetic patients could also
prevent vascular complications of diabetes mellitus.  
Conclusions
Patients with diabetes mellitus have more aggravating
past medical history with more frequently coexisting
comorbidities like previous MI, hypertension and stroke.
Diabetes mellitus in patients with ACS treated by PCI and
PTA is associated with impaired 1-year survival. However,
no differences were found in combined study primary and
secondary endpoints. Diabetes itself is a strong predictor
of repeated PTA procedures. 
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